Last reviewed · How we verify
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol is a Anti-tuberculosis combination therapy Small molecule drug developed by Tuberculosis Research Centre, India. It is currently in Phase 3 development for Tuberculosis (drug-susceptible and potentially drug-resistant forms).
This is a fixed-dose combination of five anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis through multiple mechanisms.
This is a fixed-dose combination of five anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis through multiple mechanisms. Used for Tuberculosis (drug-susceptible and potentially drug-resistant forms).
At a glance
| Generic name | Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol |
|---|---|
| Sponsor | Tuberculosis Research Centre, India |
| Drug class | Anti-tuberculosis combination therapy |
| Target | Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase; Isoniazid and Rifampicin inhibit mycobacterial cell wall synthesis and RNA polymerase respectively; Pyrazinamide disrupts bacterial metabolism; and Ethambutol inhibits cell wall arabinan synthesis. Together, these agents provide broad coverage against drug-susceptible and some drug-resistant tuberculosis strains.
Approved indications
- Tuberculosis (drug-susceptible and potentially drug-resistant forms)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Arthralgia
- Photosensitivity (moxifloxacin)
- Hyperuricemia (pyrazinamide)
Key clinical trials
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A PAN-USR TB Multi-Center Trial (PHASE3)
- B-PaLMZ for TB Meningitis (PHASE2)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- PanACEA - STEP2C -01 (PHASE2)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol CI brief — competitive landscape report
- Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol updates RSS · CI watch RSS
- Tuberculosis Research Centre, India portfolio CI
Frequently asked questions about Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
What is Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol?
How does Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol work?
What is Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol used for?
Who makes Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol?
What drug class is Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol in?
What development phase is Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol in?
What are the side effects of Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol?
What does Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol target?
Related
- Drug class: All Anti-tuberculosis combination therapy drugs
- Target: All drugs targeting Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)
- Manufacturer: Tuberculosis Research Centre, India — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Tuberculosis (drug-susceptible and potentially drug-resistant forms)